COPENHAGEN, Denmark--(BUSINESS WIRE)--Helion Biotech, which was founded based on research from Aarhus University, Denmark, announced today that it has received funding from leading Danish life science investor group, SEED Capital Denmark. The proceeds will be used to continue further development of the company’s lead project, recombinant human protein MASP-2, which is in pre-clinical development.
